
Treatment for leukodystrophy could be “revolutionary”
The US Food and Drug Administration (FDA) has granted Rare Paediatric Disease (RPD) Designation to SynaptixBio’s drug candidate for TUBB4a leukodystrophy – a genetic and debilitating condition which mainly affects babies and young children. RPDs are designed to encourage the development of new drugs with high unmet medical needs, including… Read More














